Portola Pharmaceuticals   Print Page    Close Window

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
October 11, 2017Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness about the Persistent Risk of Blood ClotsPrinter Friendly Version
October 03, 2017Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
September 12, 2017Portola Announces Pricing of Public Offering of Common StockPrinter Friendly Version
September 11, 2017Portola Pharmaceuticals Announces Proposed Offering of Common StockPrinter Friendly Version
September 06, 2017Portola Pharmaceuticals to Present at the 2017 Morgan Stanley Global Healthcare ConferencePrinter Friendly Version
September 05, 2017Reminder: Portola Pharmaceuticals to Host Webcast and Conference Call Today, Tuesday, Sept. 5 to Provide Further Details on Bevyxxa® (betrixaban) LaunchPrinter Friendly Version
September 01, 2017Portola Pharmaceuticals to Host Webcast and Conference Call Tuesday, Sept. 5 to Provide Further Details on Bevyxxa® (betrixaban) LaunchPrinter Friendly Version
August 21, 2017Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and Andexanet Alfa at the European Society of Cardiology (ESC) Congress 2017Printer Friendly Version
August 15, 2017Portola Pharmaceuticals Announces AndexXa® (Andexanet Alfa) Biologics License Application Resubmission Accepted for Review by U.S. FDAPrinter Friendly Version
August 09, 2017Portola Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate UpdatePrinter Friendly Version
August 03, 2017Portola Pharmaceuticals Announces Resubmission of Biologics License Application for AndexXa® (Andexanet Alfa)Printer Friendly Version
August 02, 2017Portola Pharmaceuticals to Announce Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, August 9Printer Friendly Version
July 27, 2017Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
July 06, 2017Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and Andexanet Alfa at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Scientific and Standardization Committee MeetingPrinter Friendly Version
June 23, 2017U.S. FDA Approves Bevyxxa® (betrixaban) First and Only Anticoagulant for Hospital and Extended Duration Prevention of Venous Thromboembolism (VTE) in Acutely Ill Medical PatientsPrinter Friendly Version
June 15, 2017Portola Pharmaceuticals Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant LymphomaPrinter Friendly Version
May 18, 2017Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association (EHA)Printer Friendly Version
May 09, 2017Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma (ICML)Printer Friendly Version
May 08, 2017Portola Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate UpdatePrinter Friendly Version
May 01, 2017Portola Pharmaceuticals to Announce First Quarter 2017 Financial Results and Host Conference Call on Monday, May 8Printer Friendly Version
March 07, 2017Portola Pharmaceuticals Announces Betrixaban and AndexXa™ (andexanet alfa) Presentations at ACC.17Printer Friendly Version
March 01, 2017Portola Pharmaceuticals to Present at Two Upcoming Investor ConferencesPrinter Friendly Version
February 28, 2017Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate UpdatePrinter Friendly Version
February 21, 2017Portola Pharmaceuticals to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, February 28Printer Friendly Version
February 08, 2017FDA Informs Portola Pharmaceuticals at Mid-Cycle Review for Betrixaban That It Has Not Identified Issues that Require an Advisory Committee MeetingPrinter Friendly Version
February 03, 2017Portola Pharmaceuticals Signs $150 Million Royalty Agreement with HealthCare Royalty Partners for Development and Commercialization of Andexanet AlfaPrinter Friendly Version
January 03, 2017Portola Pharmaceuticals to Webcast Corporate Update on January 10, 2017Printer Friendly Version